All In Biotech

Drug Trial Radar · NCT04165096

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

128

Actual

Start

Jan 21, 2020

Primary completion

Apr 30, 2025

Study completion May 28, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • PembrolizumabBiological

    IV infusion

  • BoserolimabBiological

    IV infusion

  • MK-4830Biological

    IV infusion

  • diphenhydramineDrug

    PO

  • acetaminophenDrug

    PO

  • MK-0482Biological

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 53 months

Locations

39 sites in 7 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center ( Site 0001)

    Gilbert, Arizona

  • City of Hope ( Site 0014)

    Duarte, California

  • UCSF Medical Center at Mission Bay ( Site 0007)

    San Francisco, California

  • Georgetown University ( Site 0036)

    Washington D.C., District of Columbia

  • University of Kentucky Markey Cancer Center ( Site 0019)

    Lexington, Kentucky

  • MedStar Franklin Square Medical Center ( Site 0033)

    Baltimore, Maryland

  • Massachusetts General Hospital ( Site 0003)

    Boston, Massachusetts

  • Dana Farber Cancer Institute ( Site 0002)

    Boston, Massachusetts

  • Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031)

    Omaha, Nebraska

  • Dartmouth Hitchcock Medical Center ( Site 0016)

    Lebanon, New Hampshire

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037)

    Hackensack, New Jersey

  • Laura and Isaac Perlmutter Cancer Center ( Site 0034)

    New York, New York

  • Sanford Fargo Medical Center ( Site 0039)

    Fargo, North Dakota

  • Cleveland Clinic Main ( Site 0006)

    Cleveland, Ohio

  • Ohio State University Comprehensive Cancer Center ( Site 0015)

    Columbus, Ohio

  • Abramson Cancer Center of the University of Pennsylvania ( Site 0010)

    Philadelphia, Pennsylvania

  • Sanford Cancer Center ( Site 0038)

    Sioux Falls, South Dakota

  • The University of Texas MD Anderson Cancer Center ( Site 0009)

    Houston, Texas

  • Orszagos Koranyi Pulmonologiai Intezet ( Site 0060)

    Budapest, Hungary

  • Petz Aladar Megyei Oktato Korhaz ( Site 0062)

    Győr, Győr-Moson-Sopron, Hungary

  • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 0061)

    Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Soroka Medical Center ( Site 0072)

    Beersheba, Israel

  • Rambam Health Care Campus-Oncology ( Site 0076)

    Haifa, Israel

  • Shaare Zedek Medical Center ( Site 0075)

    Jerusalem, Israel

  • Meir Medical Center ( Site 0071)

    Kfar Saba, Israel

  • Rabin Medical Center ( Site 0074)

    Petah Tikva, Israel

  • Chaim Sheba Medical Center ( Site 0070)

    Ramat Gan, Israel

  • Sourasky Medical Center ( Site 0077)

    Tel Aviv, Israel

  • IRCCS Ospedale San Raffaele ( Site 0171)

    Milan, Italy

  • Azienda Ospedaliera Universitaria Careggi ( Site 0173)

    Florence, Firenze, Italy

  • Policlinico Gemelli di Roma ( Site 0174)

    Rome, Lazio, Italy

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)

    Gdansk, Pomeranian Voivodeship, Poland

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)

    Koszalin, West Pomeranian Voivodeship, Poland

  • Severance Hospital ( Site 0080)

    Seoul, South Korea

  • Samsung Medical Center ( Site 0082)

    Seoul, South Korea

  • Seoul National University Bundang Hospital ( Site 0081)

    Seongnam-si, Kyonggi-do, South Korea

  • ICO L Hospitalet ( Site 0090)

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Hospital Universitario Quiron Madrid ( Site 0091)

    Pozuelo de Alarcón, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.